NGeneBio is conducting the study of molecular mechanisms of metastatic prostate cancer-related gene mutations with Asan Medical Center. The study is the first molecular epidemiological clinical study of metastatic prostate cancer that analyzes HRD-related gene mutations including the BRCA 1/2 gene with 15 hospitals in South Korea. To accurately confirm the frequency of gene mutations, NGeneBio plans to comprehensively analyze the NGS test results of more than 300 Korean patients.

For the full Korean press release, head over to the below link.


May 28, 2021 @South Korea